NO175066C - - Google Patents

Info

Publication number
NO175066C
NO175066C NO861482A NO861482A NO175066C NO 175066 C NO175066 C NO 175066C NO 861482 A NO861482 A NO 861482A NO 861482 A NO861482 A NO 861482A NO 175066 C NO175066 C NO 175066C
Authority
NO
Norway
Prior art keywords
factor
protein
encoding
sequence
downstream
Prior art date
Application number
NO861482A
Other languages
English (en)
Norwegian (no)
Other versions
NO175066B (no
NO861482L (no
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO861482L publication Critical patent/NO861482L/no
Publication of NO175066B publication Critical patent/NO175066B/no
Publication of NO175066C publication Critical patent/NO175066C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Retarders (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
NO861482A 1985-04-17 1986-04-16 DNA-konstruksjon, plasmid og fremgangsmåte for ekspresjon av faktor VII og IX aktiviteter i pattedyrceller NO175066B (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431185A 1985-04-17 1985-04-17
US06/810,002 US4784950A (en) 1985-04-17 1986-12-16 Expression of factor VII activity in mammalian cells

Publications (3)

Publication Number Publication Date
NO861482L NO861482L (no) 1986-10-20
NO175066B NO175066B (no) 1994-05-16
NO175066C true NO175066C (fi) 1994-08-24

Family

ID=27110961

Family Applications (3)

Application Number Title Priority Date Filing Date
NO861482A NO175066B (no) 1985-04-17 1986-04-16 DNA-konstruksjon, plasmid og fremgangsmåte for ekspresjon av faktor VII og IX aktiviteter i pattedyrceller
NO1996007C NO1996007I1 (no) 1985-04-17 1996-06-26 Human koagulasjons faktor VII (FVII)
NO1996012C NO1996012I1 (no) 1985-04-17 1996-10-21 Betaferon

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO1996007C NO1996007I1 (no) 1985-04-17 1996-06-26 Human koagulasjons faktor VII (FVII)
NO1996012C NO1996012I1 (no) 1985-04-17 1996-10-21 Betaferon

Country Status (18)

Country Link
US (1) US4784950A (fi)
EP (1) EP0200421B1 (fi)
JP (4) JPH0824587B2 (fi)
CN (1) CN1032142C (fi)
AT (1) ATE92105T1 (fi)
AU (1) AU603983B2 (fi)
CA (1) CA1340512C (fi)
DE (1) DE3688760T2 (fi)
DK (2) DK175616B1 (fi)
ES (1) ES8800343A1 (fi)
FI (1) FI100055B (fi)
GR (1) GR860984B (fi)
HU (1) HU204556B (fi)
IE (1) IE61982B1 (fi)
LU (1) LU88806I2 (fi)
NO (3) NO175066B (fi)
NZ (1) NZ215842A (fi)
PT (1) PT82408B (fi)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
CA1281647C (en) * 1985-11-26 1991-03-19 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
IL82648A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Human protein s,a plasma protein regulator of hemostasis
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) * 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
WO1988003926A1 (en) * 1986-11-17 1988-06-02 New England Medical Center Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
FI882746A (fi) * 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
WO1991011514A1 (en) * 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
DE4007902A1 (de) * 1990-03-13 1991-09-19 Behringwerke Ag Synthetische peptide, die sequenzen aus faktor viia enthalten und deren verwendung
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5876985A (en) * 1991-04-25 1999-03-02 Board Of Regents, The University Of Texas System Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5965350A (en) * 1994-04-08 1999-10-12 Syntex (U.S.A.) Inc. Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
DK1632574T3 (da) 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
DE69841434D1 (de) 1997-07-18 2010-02-25 Novo Nordisk Healthcare Ag VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
EP0927764B1 (de) * 1997-12-03 2004-05-26 Boehringer Mannheim Gmbh Chimäre Serinproteasen
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DK1115862T3 (da) 1998-09-23 2009-11-16 Zymogenetics Inc Cytokinreceptor Zalpha11
MX343200B (es) 1998-11-27 2016-10-19 Ucb Pharma Sa Composiciones y metodos para aumentar la mineralizacion ósea.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000034474A2 (en) 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
NZ512753A (en) 1999-01-07 2003-10-31 Zymogenetics Inc Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AU3273200A (en) 1999-03-15 2000-10-04 Novo Nordisk A/S Ion exchange chromatographic separation of glp-1 and related peptides
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
EP2258725A3 (en) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP1717316B1 (en) 2000-06-30 2008-08-13 ZymoGenetics, Inc. Allelic variant of the Interferon-like protein ZCYTO21
CN100475959C (zh) 2000-09-13 2009-04-08 诺沃挪第克健康护理股份公司 人凝血因子vii变体
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
FR2814170B1 (fr) * 2000-09-18 2005-05-27 Rhodia Chimie Sa Nouveau latex a proprietes de surface modifiees par l' ajout d'un copolymere hydrosoluble a caractere amphiphile
CA2422214A1 (en) * 2000-10-02 2002-04-11 Novo Nordisk A/S Factor vii glycoforms
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
US7615537B2 (en) * 2000-10-25 2009-11-10 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
JP2004529640A (ja) 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
AU2002244757A1 (en) * 2001-04-02 2002-10-15 Bayer Aktiengesellschaft Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
ATE405586T1 (de) 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
DK2279753T3 (en) 2001-10-10 2015-11-23 Novo Nordisk As The conversion of peptides and glycokonjugering
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2464527A1 (en) * 2001-10-26 2003-08-14 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
DK1451322T3 (da) 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
JP2005511601A (ja) * 2001-11-09 2005-04-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび組織プラスミノゲン阻害剤を含む薬学的組成物
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
JP2005515175A (ja) * 2001-11-09 2005-05-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびアルファ２−抗プラスミンポリペプチドを含む薬学的組成物
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7494804B2 (en) 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
WO2003089603A2 (en) 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
PL373728A1 (en) * 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
JP4648002B2 (ja) * 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
PT1517710E (pt) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
US6933136B2 (en) * 2002-09-20 2005-08-23 Novo Nordisk A/S Method for making recombinant proteins
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
AU2003266214A1 (en) 2002-09-25 2004-04-19 Novo Nordisk A/S Human coagulation factor vii polypeptides
EP1611236A1 (en) 2003-03-18 2006-01-04 Novo Nordisk Health Care AG Method for the production of gla-residue containing serine proteases
RU2005132164A (ru) * 2003-03-18 2006-06-10 Ново Нордиск Хелт Кэр Аг (Ch) Жидкие, водные фармацевтические композиции полипептидов фактора vii
ES2327044T3 (es) * 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
CA2522690A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1628677B1 (en) * 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005044849A2 (en) * 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP2275432A1 (en) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration of factor VII solutions to remove virus
PT2298287T (pt) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Composições estabilizadas de polipéptidos de fator vii
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
EP1732946B1 (en) 2004-03-08 2011-07-27 ZymoGenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006012644A2 (en) 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
ES2346072T3 (es) * 2004-08-17 2010-10-08 Csl Behring Gmbh Polipeptidos modificados dependientes de la vitamina k.
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
PL1831242T3 (pl) 2004-12-23 2013-04-30 Novo Nordisk Healthcare Ag Zmniejszanie zawartości zanieczyszczeń białkowych w kompozycjach zawierających zależne od witaminy K białko będące przedmiotem zainteresowania
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
MX2007012704A (es) * 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
JP2008543925A (ja) * 2005-06-24 2008-12-04 ダラグレキュル・アンパルトセルスカブ 呼吸器系に影響を及ぼす炎症状態における組織因子系凝固インヒビターの気道投与
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
UA93516C2 (ru) * 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
ES2399138T3 (es) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Tratamiento local con factor VII
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
NZ572373A (en) * 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
ES2889920T3 (es) 2006-06-14 2022-01-14 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
JP2010510992A (ja) 2006-11-30 2010-04-08 ユニバーシティー オブ ブリティッシュ コロンビア 分子アジュバンドとしてのｔａｐ−１及び／又はｔａｐ−２を含むポックスウイルスの治療
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
KR20100016462A (ko) * 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
KR101818411B1 (ko) 2007-12-27 2018-01-12 박스알타 인코퍼레이티드 세포 배양 방법
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2623112B1 (en) 2008-06-27 2015-03-04 Zymogenetics, Inc. Soluble hybrid Fc gamma receptors and related methods
PT2356247E (pt) 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
FR2942231B1 (fr) 2009-02-19 2015-03-20 Lfb Biotechnologies Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2467166A2 (en) 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
EP2494040B1 (en) * 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Method of producing recombinant vitamin k dependent proteins
JP5984676B2 (ja) 2009-12-18 2016-09-06 シーエスエル、リミテッド ポリペプチドを精製する方法
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
EP2580238A1 (en) 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
EP2633058B1 (en) * 2010-10-26 2016-07-20 Hanmi Science Co., Ltd. Method for mass production of factor vii/viia
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9150846B2 (en) 2011-07-05 2015-10-06 Bioasis Technologies, Inc. P97-antibody conjugates and methods of use
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN104220602B (zh) 2012-02-01 2018-10-30 合成基因组股份有限公司 用于合成错误最小化核酸分子的材料和方法
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
ES2771208T3 (es) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
JP2015534573A (ja) 2012-10-10 2015-12-03 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子ポリペプチドの液体医薬組成物
EP2906247A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Factor vii conjugates
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
US9925276B2 (en) 2013-03-14 2018-03-27 Epeius Biotechnologies Corporation Thymidine kinase gene
AU2013204728B2 (en) 2013-03-15 2016-09-15 Baxalta GmbH Methods for treating bleeding disorders using a platelet subpopulation
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US20160347821A1 (en) 2014-02-03 2016-12-01 Bioasis Technologies, Inc. P97 fusion proteins
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
US20180169297A1 (en) 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
EP3328881B1 (en) 2015-09-08 2019-08-28 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019094521A1 (en) 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
RU2756100C1 (ru) 2017-12-20 2021-09-28 Харбор Байомед (Шанхай) Ко., Лтд Антитела, связывающие ctla-4, и их применение
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2019132765A1 (en) 2017-12-27 2019-07-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
NZ769677A (en) 2018-05-18 2024-07-05 Bioverativ Therapeutics Inc Methods of treating hemophilia a
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
MX2021011824A (es) * 2019-03-27 2021-12-10 Sigilon Therapeutics Inc Composiciones, dispositivos y metodos para la terapia del factor vii.
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021262081A1 (en) 2020-06-22 2021-12-30 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
EP4203989A2 (en) 2020-09-03 2023-07-05 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022178090A2 (en) 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
WO2024042148A1 (en) 2022-08-26 2024-02-29 Stellaris Pharmaceuticals Aps Haemorrhage inhibiting compositions and methods involving the same
WO2024148328A2 (en) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Bispecific pd-l1 and cd40 binding molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
AU560686B2 (en) * 1982-08-04 1987-04-16 British Technology Group Limited Cloning vehicle dna h-factor ix elements

Also Published As

Publication number Publication date
HU204556B (en) 1992-01-28
IE61982B1 (en) 1994-12-14
FI861598A (fi) 1986-10-18
CN86102644A (zh) 1987-06-03
LU88806I2 (fr) 1997-01-03
DE3688760D1 (de) 1993-09-02
JPH10117787A (ja) 1998-05-12
US4784950A (en) 1988-11-15
DE3688760T2 (de) 1993-10-28
AU603983B2 (en) 1990-12-06
NO175066B (no) 1994-05-16
DK175616B1 (da) 2004-12-27
HUT43634A (en) 1987-11-30
JPH0824587B2 (ja) 1996-03-13
EP0200421B1 (en) 1993-07-28
JP2835038B2 (ja) 1998-12-14
NZ215842A (en) 1988-04-29
PT82408A (en) 1986-05-01
EP0200421A3 (en) 1987-06-03
FI100055B (fi) 1997-09-15
AU5617786A (en) 1986-11-06
CA1340512C (en) 1999-04-27
JP2544090B2 (ja) 1996-10-16
NO861482L (no) 1986-10-20
CN1032142C (zh) 1996-06-26
EP0200421A2 (en) 1986-11-05
JP2726806B2 (ja) 1998-03-11
DK177386A (da) 1986-10-18
JPH07163375A (ja) 1995-06-27
ATE92105T1 (de) 1993-08-15
NO1996007I1 (no) 1996-06-26
ES554038A0 (es) 1987-11-01
JPH07163374A (ja) 1995-06-27
JPS62283A (ja) 1987-01-06
GR860984B (en) 1986-08-18
IE860995L (en) 1986-10-17
FI861598A0 (fi) 1986-04-16
ES8800343A1 (es) 1987-11-01
NO1996012I1 (no) 1996-10-21
DK200401261A (da) 2004-08-20
PT82408B (pt) 1988-08-17
DK177386D0 (da) 1986-04-17

Similar Documents

Publication Publication Date Title
NO175066C (fi)
AU4814885A (en) Modified tissue plasminogen activator produced by recombinant DNA
DE3686217D1 (de) Alkalische protease, verfahren zur herstellung von hybridvektoren und genetisch transformierte mikroorganismen.
DK567087D0 (da) Dna-sekvens, der koder for et protein med i alt vaesentligt samme biologiske aktivitet som humanprotein c, samt fremgangsmaade til fremstilling af dette protein
FI862756A (fi) Fibroektiner.
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
FI943122A0 (fi) Menetelmiä trombiinin tuottamiseksi
KR880013978A (ko) 피브린 분해 단백질
Marcum et al. Species specificity of streptokinase
PT641215E (pt) Analogos de trombomodulina resistentes a proteases
DE3481417D1 (de) Kontinuierliche, katalytische epoxidation von olefinischen doppelbindungen mit wasserstoffperoxid und ameisensaeure.
ATE105480T1 (de) Thrombin bindende substanz und verfahren zu ihrer herstellung.
DK0544826T3 (da) Overlegne trombomodulinanaloger til farmaceutisk anvendelse
ES2067556T3 (es) Vectores de expresion de adn recombinante y compuestos de adn que codifican la actividad isopenicilina n epimerasa (racemasa).
EP0210279A4 (en) STABILIZED HUMAN PROUROKINASE.
ATE135408T1 (de) Für ein protein mit der fähigkeit zur zusammenwirkung mit dem enhancer des alpha- fetoproteingens kodierende dna
NL960017I1 (nl) Expressie van Factor VIII-activiteit in zoogdiercellen.
Fořtová et al. Isolation of a fibrinogen-converting enzyme ficozyme from the venom of Bothrops asper by one-step affinity chromatography on Blue Sepharose
AU740727B2 (en) Activated vitamin K-dependent blood factor and method for the production thereof
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
EP0218432A3 (en) Methods for cdna cloning, and vector-primer dna, plasmid dna and linker dna, used in the said methods
Zhong Role of the first epidermal growth factor-like domain in factor IX function.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees
ERR Erratum

Free format text: I PATENTTIDENDE NR. 53/04 BLE PATENT NR. 175066 FEILAKTIG KUNNGJORT TRADT UT AV KRAFT. PATENTET ER FORTSATT I KRAFT.

MK1K Patent expired